Citius Pharmaceuticals Inc (CTXR)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Citius Pharmaceuticals Inc chart...

About the Company

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Employees

10

CEO

Myron Holubiak

Exchange

NASDAQ

Website

www.citiuspharma.com

$M

Total Revenue

10

Employees

$138M

Market Capitalization

-5.31

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CTXR News

Citius Pharmaceuticals Inc CTXR

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

20d ago, source: WATE 6 On Your Side

CRANFORD, N.J., March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

1mon ago, source: KOIN 6

NOTE: This content is not written by or endorsed by "KOIN", its advertisers, or Nexstar Media Inc.

Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts

9d ago, source:

Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, ...

Citius Pharmaceuticals Inc

7d ago, source: CNN

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct ...

Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts

9d ago, source: Business Insider

(RTTNews) - Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, an IL-2-based immunotherapy for the treatment of ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

2mon ago, source: Stockhouse

Likewise, our upcoming end of Phase 2 meeting with the FDA should provide valuable input on the development plan for Halo-Lido," stated Leonard Mazur, Chairman and CEO of Citius. "Importantly, we ...

Citius Pharmaceuticals Inc CTXR

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Citius Pharmaceuticals Inc (CTXR)

21d ago, source: Investing

Investing.com - Citius Pharma (NASDAQ: CTXR) reported third quarter EPS of $-0.060, in line with the analyst estimate of $-0.060. Revenue for the quarter came in at $0.00 versus... Citius Pharma ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...